Taimur H. Sher
Experienced in Non-Small Cell Lung Cancer (NSCLC)

Dr. Taimur H. Sher

Hematology Oncology | Hematology | Oncology
Mayo Clinic Jacksonville
4500 San Pablo Rd S, 
Jacksonville, FL 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Experienced in Non-Small Cell Lung Cancer (NSCLC)
Mayo Clinic Jacksonville
4500 San Pablo Rd S, 
Jacksonville, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Taimur Sher is a Hematologist Oncology specialist and a Hematologist in Jacksonville, Florida. Dr. Sher is rated as an Experienced provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Primary Amyloidosis, Multiple Myeloma, Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Sher is currently accepting new patients.

His clinical research consists of co-authoring 106 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in FL
Hospital Affiliations
Mayo Clinic
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

MAYO CLINIC JACKSONVILLE
4500 San Pablo Rd S, Jacksonville, FL 32224

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Phase2 Trial of High Dose Intravenous Ascorbic Acid as an Adjunct to Salvage Chemotherapy in Relapsed/ Refractory Lymphoma, Patients With Clonal Cytopenia of Undetermined Significance, and Chronic Myelomonocytic Leukemia
Phase2 Trial of High Dose Intravenous Ascorbic Acid as an Adjunct to Salvage Chemotherapy in Relapsed/ Refractory Lymphoma, Patients With Clonal Cytopenia of Undetermined Significance, and Chronic Myelomonocytic Leukemia
Enrollment Status: Recruiting
Publish Date: July 16, 2025
Intervention Type: Procedure, Drug, Biological, Other, Dietary supplement
Study Drugs: Carboplatin, Cisplatin, Cytarabine, Dexamethasone, Etoposide, Gemcitabine Hydrochloride, Ifosfamide, Oxaliplatin, Rituximab
Study Phase: Phase 2
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A (Apilimod Dimesylate Capsules) Administered Orally in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A (Apilimod Dimesylate Capsules) Administered Orally in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Enrollment Status: Completed
Publish Date: August 22, 2024
Intervention Type: Drug
Study Drugs: Apilimod, Rituximab, Atezolizumab
Study Phase: Phase 1
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
Enrollment Status: Terminated
Publish Date: November 14, 2023
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies
A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: December 08, 2021
Intervention Type: Drug
Study Drugs: INCB053914, I-DAC (Intermediate Dose Cytarabine), Azacitidine, Ruxolitinib
Study Phase: Phase 1/Phase 2
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Who Have Persistent Cardiac Dysfunction
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Who Have Persistent Cardiac Dysfunction
Enrollment Status: Completed
Publish Date: April 05, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects With Light Chain (AL) Amyloidosis Who Were Previously Enrolled in Study NEOD001-201 (PRONTO)
A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects With Light Chain (AL) Amyloidosis Who Were Previously Enrolled in Study NEOD001-201 (PRONTO)
Enrollment Status: Terminated
Publish Date: March 26, 2019
Intervention Type: Drug
Study Phase: Phase 2
Phase II Study of Ibrutinib With or Without Bortezomib and Dexamethasone for the Treatment of Patients With Relapsed/Refractory Immunoglobulin Light Chain Amyloidosis
Phase II Study of Ibrutinib With or Without Bortezomib and Dexamethasone for the Treatment of Patients With Relapsed/Refractory Immunoglobulin Light Chain Amyloidosis
Enrollment Status: Withdrawn
Publish Date: March 02, 2018
Intervention Type: Drug, Other
Study Phase: Phase 2
View 6 Less Clinical Trials

106 Total Publications

Cardiac Troponin T Elevation Predicts Mortality in Hospitalized COVID-19 Patients.
Cardiac Troponin T Elevation Predicts Mortality in Hospitalized COVID-19 Patients.
Journal: medRxiv : the preprint server for health sciences
Published: July 09, 2025
Similar Doctors
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Yanyan T. Lou
Hematology Oncology | Hematology | Oncology
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Yanyan T. Lou
Hematology Oncology | Hematology | Oncology

Mayo Clinic Jacksonville

4500 San Pablo Rd S, 
Jacksonville, FL 
 (0.1 miles away)
904-953-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Yanyan Lou is a Hematologist Oncology specialist and a Hematologist in Jacksonville, Florida. Dr. Lou is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). Her top areas of expertise are Lung Adenocarcinoma, Lung Cancer, Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), and Tissue Biopsy. Dr. Lou is currently accepting new patients.

Distinguished in Non-Small Cell Lung Cancer (NSCLC)
Dr. Rami Manochakian
Hematology Oncology | Hematology | Oncology
Distinguished in Non-Small Cell Lung Cancer (NSCLC)
Dr. Rami Manochakian
Hematology Oncology | Hematology | Oncology

Mayo Clinic Jacksonville

4500 San Pablo Rd S, 
Jacksonville, FL 
 (0.1 miles away)
904-953-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rami Manochakian is a Hematologist Oncology specialist and a Hematologist in Jacksonville, Florida. Dr. Manochakian is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), and Pleuropulmonary Blastoma. Dr. Manochakian is currently accepting new patients.

Distinguished in Non-Small Cell Lung Cancer (NSCLC)
Dr. John H. Vu
Oncology | Hematology
Distinguished in Non-Small Cell Lung Cancer (NSCLC)
Dr. John H. Vu
Oncology | Hematology

Baptist MD Anderson Cancer Physicians Inc

14546 Old Saint Augustine Rd, Suite 105, 
Jacksonville, FL 
 (10.3 miles away)
904-202-7300
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Vu is an Oncologist and a Hematologist in Jacksonville, Florida. Dr. Vu is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, and EGFR Positive Lung Cancer. Dr. Vu is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sher's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 14 Advanced Conditions
View All 98 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile